Interestingly, of the 173 patients with negative PSMA PET/CT, pN1 was found in 20%, thus suggesting the importance of performing ePLND in intermediate-risk and high-risk prostate cancer patients, even with a negative PSMA PET/CT scan [20▪▪]. The gene discussed is FOLH1; the disease is prostate carcinoma.